In short
Clinical trials are investigating Imetelstat Sodium in people with blood cancers such as myelofibrosis, myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML). These studies look at safety, efficacy, survival, and transfusion needs in patients whose disease has not responded to prior treatments.
Key points
- Clinical trials of Imetelstat Sodium are studying blood cancers, mainly myelofibrosis, myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML). The studies include Phase 2, Phase 3, and Phase 4 research, so they are looking at both early and later questions about benefit and safety. Some trials focus on patients whose disease did not respond to earlier treatment, such as HMA-based therapy or JAK-inhibitor treatment. One major MDS study also focuses on people who need regular red blood cell transfusions. The main outcomes include overall response rate, overall survival, and transfusion independence.
Clinical trials overview
The available studies on Imetelstat Sodium are testing it in people with blood cancers and related bone marrow disorders.
The trial set includes one withdrawn Phase 2 study, two authorised Phase 2 studies with the same MDS/AML focus, one authorised Phase 3 study in myelofibrosis, and one authorised Phase 4 study in lower-risk MDS.
Trials in MDS and AML after prior treatment failure
Two Phase 2 studies evaluate efficacy and safety in patients with AML or MDS who are failing or refractory to hypomethylating agent (HMA)-based treatment.
These studies are interventional, which means participants receive study treatment rather than only being observed.
Both trials plan to enroll 46 participants and use a primary outcome of overall response rate after 4 months of treatment.
The response is measured using combined criteria for MDS and AML, based on IWG 2018 criteria for MDS and European LeukemiaNet criteria for AML.
One of these Phase 2 studies is withdrawn, while the other is authorised.
Trial in myelofibrosis after JAK-inhibitor treatment
The Phase 3 study in myelofibrosis compares Imetelstat Sodium with best available therapy (BAT) in people with intermediate-2 or high-risk disease that is relapsed or refractory to JAK-inhibitor treatment.
This study is larger than the Phase 2 trials and plans to enroll 354 participants.
The main endpoint is overall survival, which means the time from randomization until death from any cause.
This endpoint helps show whether one treatment helps people live longer than the other treatment strategy.
Trial in transfusion-dependent low-risk MDS
The Phase 4 study looks at subjects with IPSS low or intermediate-1 risk MDS who are transfusion dependent and relapsed or refractory to ESA treatment.
This study includes a comparison with placebo in one part of the trial and also has an extension phase for longer follow-up.
The trial plans to enroll 224 participants.
The main efficacy endpoint is red blood cell transfusion independence lasting at least 8 weeks, meaning no red blood cell transfusions during a continuous 8-week period.
The extension phase also looks at long-term safety, overall survival, and disease progression, including progression to AML.
Main endpoints and what they mean
Overall response rate is the percentage of people whose disease improves based on study rules.
Overall survival measures how long participants live after starting the study treatment.
Red blood cell transfusion independence measures time without needing red blood cell transfusions, which is important for people with transfusion-dependent MDS.
Some studies also track long-term safety and disease progression, which helps researchers understand whether the treatment may help control the disease over time.
Who the trials are for
The trial populations are adults with specific blood cancers or bone marrow disorders, especially those whose disease has not responded to earlier treatment.
Some studies focus on people with AML or MDS after HMA-based treatment failure, while others focus on myelofibrosis after JAK-inhibitor treatment or on transfusion-dependent lower-risk MDS after ESA treatment.
These differences show that the trials are not general studies for all patients with blood cancer, but targeted studies for specific groups with unmet treatment needs.